In ambiguous cases, immunohistochemistry showing the loss of the RB1 protein is a powerful indicator of a poorly differentiated neuroendocrine carcinoma (NEC). This helps distinguish NECs from high-grade neuroendocrine tumors or adenocarcinomas with neuroendocrine features, a critical distinction for prognosis and treatment.
The primary site of a neuroendocrine neoplasm offers strong diagnostic clues. For example, tumors in the esophagus or gallbladder are almost always poorly-differentiated NECs, while those in the mid-colon are also typically NECs. This site-specificity serves as a powerful diagnostic heuristic for clinicians.
A patient's clinical history can override ambiguous histology. A high-grade neuroendocrine neoplasm in a patient with a prior well-differentiated NET is almost certainly a progressive G3 NET, not a poorly differentiated NEC, as the two tumor types follow distinct biological progression pathways.
The novel target DLL3 is a promising avenue for treating NECs, but its therapeutic efficacy is highly dependent on expression levels. Early trial data for a DLL3 T-cell engager showed a 40% response rate in high-expressing tumors versus just 3% in low-expressors, mandating biomarker testing for patient selection.
Well-differentiated NETs and poorly-differentiated NECs show opposite results on key functional imaging scans. NETs are typically avid on somatostatin receptor imaging (DOTATATE-PET) but negative on FDG-PET. Aggressive NECs show the reverse profile, being highly avid on FDG-PET. This provides a crucial non-invasive diagnostic clue.
Despite widespread use in oncology, immunotherapy has limited efficacy in extrapulmonary NEC. Real-world data for combination CTLA-4 and PD-1 inhibitors show response rates around 15%, with sustained responses in less than 10% of patients. This highlights the urgent need for novel therapeutic approaches beyond checkpoint inhibition.